What is Taysha Gene Therapies, Inc. (TSHA) stock price today?

Taysha Gene Therapies, Inc. (TSHA) is currently trading at $4.49, up 1.24% today.

What is TSHA P/E ratio?

Taysha Gene Therapies, Inc.'s P/E ratio is -10.62. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is TSHA return on equity (ROE)?

Taysha Gene Therapies, Inc.'s return on equity (ROE) is -56.19%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Taysha Gene Therapies, Inc.'s market cap?

Taysha Gene Therapies, Inc. has a market capitalization of $1.43B.

NASDAQ · Biotechnology

Taysha Gene Therapies, Inc. (TSHA) Stock

$4.49 +1.24% NASDAQ: TSHA Healthcare

Valuation

Metric	Value
Price	$4.49
Market Cap	$1.43B
P/E Ratio	-10.62
P/B Ratio	4.28
P/S Ratio	261.84
EPS (TTM)	$-0.41
52-Week High	$7.30
52-Week Low	$3.69
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-56.19%
ROA	-31.81%
ROCE	-34.46%
Gross Margin	88.22%
Operating Margin	-17.74%
Net Margin	-17.38%
Debt/Equity	0.14
Current Ratio	12.04

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$3.0M	$15.0M	$8.0M	$10.0M
Operating Profit	$-173.0M	$-126.0M	$-72.0M	$-91.0M	$-110.0M
Net Profit	$-175.0M	$-166.0M	$-112.0M	$-89.0M	$-109.0M
EPS	$-4.64	$-3.78	$-0.96	$-0.36	$-0.34
Op Margin	—	-5037.1%	-468.8%	-1097.5%	-1130.7%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$214.0M	$126.0M	$173.0M	$160.0M	$343.0M
Total Liabilities	$119.0M	$125.0M	$98.0M	$89.0M	$96.0M
Cash	$149.0M	$88.0M	$144.0M	$139.0M	$320.0M
Borrowings	$63.0M	$60.0M	$61.0M	$63.0M	$18.0M

Latest News

Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In Insider Monkey · Jul 15, 2026 Taysha Gene Therapies Insider Sold Shares Worth $1,248,000, According to a Recent SEC Filing MT Newswires · Jul 13, 2026 Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run Motley Fool · Jul 12, 2026 Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting GlobeNewswire · Jun 25, 2026 Sector Update: Health Care Stocks Mixed Pre-Bell Thursday MT Newswires · Jun 25, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-117.0M	$-88.0M	$-73.0M	$-81.0M	$-93.0M
Investing Cash Flow	$-43.0M	$-50.0M	$-15.0M	$-1.0M	$-1.0M
Financing Cash Flow	$-1.0M	$-1.0M	$-1.0M	$0	$0
Net Cash Flow	$-100.0M	$-61.0M	$56.0M	$-5.0M	$181.0M
Free Cash Flow	$-139.0M	$-113.0M	$-80.0M	$-82.0M	$-94.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.64
EV / EBITDA	-6.97
FCF Yield	-9.44%
Quick Ratio	17.76
Interest Coverage	-3646.64
Return 1Y	116.73%
Return 3Y	770.15%
Return 5Y	-70.96%

Ownership

Insiders Held9.63%

Institutions Held86.20%

Institutions Float Held95.38%

Institutional Holder	Shares	Report Date
RA Capital Management, L.P.	23,555,648	2026-03-31
Goldman Sachs Group Inc	22,369,645	2026-03-31
Avoro Capital Advisors LLC	21,700,000	2026-03-31
Blackrock Inc.	18,365,608	2026-03-31
Vestal Point Capital, LP	18,000,000	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$337.01	-1.00%	38.93	$4.95T	0.32%
MSFTMicrosoft Corporation	$535.56	+2.48%	28.68	$3.98T	0.76%
GOOGLAlphabet Inc.	$351.83	+1.01%	16.94	$4.26T	0.26%
AMZNAmazon.com, Inc.	$262.58	+3.35%	19.82	$2.82T	0.00%
METAMeta Platforms, Inc.	$719.34	-0.22%	27.93	$1.83T	0.28%

About Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc. is led by CEO Sean Nolan, employs 73 people, headquartered in US, publicly traded since 2020.

Taysha Gene Therapies, Inc. (TSHA) stock trades at $4.49 with a market capitalization of $1.43B. The stock is valued at a price-to-earnings (P/E) ratio of -10.62, price-to-book of 4.28, price-to-sales of 261.84. Over the past 52 weeks the stock has ranged between $3.69 and $7.30, and currently trades 38.5% below its 52-week high.

On profitability, Taysha Gene Therapies, Inc. generates a return on equity (ROE) of -56.19%, return on capital employed of -34.46%, an operating margin of -17.74%, a net profit margin of -17.38%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1175.87 +0.54% JNJ Johnson & Johnson $261.29 +1.88% ABBV AbbVie Inc. $276.40 +1.46% MRK Merck & Company, Inc. Common Stock (new) $146.30 +2.75% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.88 +2.41% NVS Novartis AG $143.79 +0.47% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $657.57 +0.86% AMGN Amgen Inc. $414.83 +1.81% GILD Gilead Sciences, Inc. $151.22 +2.80% ABT Abbott Laboratories $99.71 +1.23% NVO Novo Nordisk A/S $38.67 +1.27%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides